A Randomized, Placebo-controlled, Double-blind Phase 2 Study With OSI-906 in Patients With Advanced HCC

A Randomized, Placebo-controlled, Double-blinded Phase 2 Study of Second-line Treatment With OSI-906 in Patients With Advanced Hepatocellular Carcinoma (HCC) After Failure of First-line Treatment With Sorafenib


Lead Sponsor: Astellas Pharma Inc

Source Astellas Pharma Inc
Brief Summary

This is a randomized, placebo-controlled, double-blind phase 2 study of OSI-906 or placebo at a continuous 150 mg twice daily (BID) dose.

Detailed Description

Adult patients with advanced HCC previously treated with sorafenib will be randomized 2:1 to receive either single agent OSI-906 or placebo

Overall Status Terminated
Start Date January 10, 2011
Completion Date December 28, 2011
Primary Completion Date November 4, 2011
Phase Phase 2
Study Type Interventional
Primary Outcome
Measure Time Frame
Time to progression (TTP) 20 months
Secondary Outcome
Measure Time Frame
Overall Survival (OS) 23 months
Progression Free Survival (PFS) 23 months
Time to Progression (including clinical progression) (TTPc) 23 months
Disease Control Rate (DCR) 23 months
Overall Response Rate 23 months
Time to progression in patients with hepatitis B virus (HBV) and/or hepatitis C virus (HVC) 23 months
Progression Free Survival in patients with HBV and/or HCV 23 months
Overall Survival in patients with HBV and/or HCV 23 months
Overall Response Rate in patients with HBV and/or HCV 23 months
Safety assessed via physical examination, vital signs, clinical laboratory tests, electrocardiograms (ECGs) and recording adverse events 23 months
Enrollment 23

Intervention Type: Drug

Intervention Name: OSI-906

Description: OSI-906 administered orally

Arm Group Label: Arm A: OSI-906

Intervention Type: Drug

Intervention Name: Placebo

Description: Matching placebo administered orally

Arm Group Label: Arm B: Placebo



Inclusion Criteria:

- Histologically confirmed diagnosis of advanced HCC. Clinical diagnosis by American Association for the Study of Liver Diseases (AASLD) criteria in cirrhotic patients is acceptable. For patients without cirrhosis histological confirmation is mandatory

- Patients must have received prior systemic treatment for advanced HCC with sorafenib and had confirmed disease progression or had discontinued sorafenib due to a drug related toxicity

- Patient has received their last dose of sorafenib at least 14 days prior to randomization

- Patient has recovered from sorafenib or investigational agent related toxicity to ≤ grade 2

- Measurable disease according to RECIST (version 1.1)

- Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0 - 1

- Child-Pugh Status A or B(7)

- Barcelona Clinic Liver Cancer (BCLC) stage B/C

- Previous local therapy (eg, surgery, radiation therapy, hepatic arterial therapy, chemoembolization, radiofrequency ablation, percutaneous ethanol injection, or cryoablation) is permitted if ≥ 21 days before randomization

- Fasting glucose ≤ 150 mg/dL (8.3 mmol/L). Concurrent use of non-insulinotropic oral antihyperglycemic therapy is permitted if the dose has been stable for ≥ 4 weeks at the time of randomization

- Following laboratory parameters (determined by laboratory):

- Platelets ≥ 60 x 10^9/L

- Hemoglobin ≥ 8.5 g/dL

- Absolute neutraphil count (ANC) ≥ 1.5 x 10^9/L

- Potassium within normal limits (supplementation may be used)

- Partial thrombopastin time (PTT) ≤ 2.3 x Upper Limit of Normal (ULN)

- Magnesium within normal limits (supplementation may be used)

- Calcium within normal limits (supplementation may be used)

- Adequate organ function (for a HCC population):

- Liver function test (LFT) ≤ 5 x ULN

- Albumin ≥ 2.8 g/dL

- Total bilirubin ≤ 2.8 mg/dL

- Creatinine ≤ 1.5 x ULN

- International normalized ratio (INR) ≤ 2.3

- Estimated life expectancy ≥ 12 weeks based on an investigator assessment of recent changes in laboratory values, performance status, and other clinical criteria

- Patients, both males and females, with reproductive potential (ie, menopausal for less than 1 year and not surgically sterilized) must agree to practice effective contraceptive measures throughout the study. Women of childbearing potential must provide a negative pregnancy test (serum or urine) within 14 days prior to randomization

- Patients must provide written informed consent to participate in the study

- Prior radiation therapy is permitted provided patients have recovered from the acute, toxic effects of radiotherapy prior to randomization. A minimum of 21 days must have elapsed between the end of radiotherapy and randomization; and

- Prior surgery is permitted provided that the surgery was done ≤ 28 days prior to randomization and adequate wound healing has occurred prior to randomization

Exclusion Criteria:

- Child-Pugh B (8 - 9) or C

- Patients who are candidates for potentially curative intervention (ie, surgical resection or transplantation)

- Type 1 diabetes mellitus or Type 2 diabetes mellitus currently requiring insulinotropic or insulin therapy

- Prior insulin-like growth factor - 1 receptor (IGF-1R) therapy

- Patients requiring interferon

- Patients with uncontrolled symptomatic ascites

- Prior investigational agent within 21 days prior to randomization

- History of poorly controlled gastrointestinal disorders that could affect the absorption of study drug (eg, Crohn's disease, ulcerative colitis, etc)

- History of organ allograft including liver transplant

- Malignancy other than HCC within the past 3 years:

- Exceptions: resected basal cell or squamous cell carcinoma of the skin, cured in situ cervical carcinoma, cured ductal carcinoma in situ of the breast, and/or cured superficial bladder cancer

- History (within last 6 months) of significant cardiovascular disease unless the disease is well-controlled. Significant cardiac disease includes second/third degree heart block; clinically significant ischemic heart disease; superior vena cava (SVC) syndrome; poorly controlled hypertension; congestive heart failure of New York Heart Association (NYHA) Class II or worse (slight limitation of physical activity; comfortable at rest, but ordinary physical activity results in fatigue, palpitation, or dyspnea)

- History of arrhythmia (multifocal premature ventricular contractions [PVCs], bigeminy, trigeminy, ventricular tachycardia, or uncontrolled atrial fibrillation) that is symptomatic or requires treatment (≥ grade 3), left bundle branch block (LBBB), or asymptomatic sustained ventricular tachycardia are not allowed. Patients with atrial fibrillation controlled by medication are not excluded

- QTcF interval at screening ≥ 450 msec

- Use of drugs that have a known risk of causing Torsades de Pointes (TdP) ('Torsades List' on www.azcert.org/medical-pros/drug-lists/by category.cfm)are prohibited within 14 days prior to randomization

- Use of the potent CYP1A2 inhibitors ciprofloxacin and fluvoxamine. Other less potent CYP1A2 inhibitors/inducers are not excluded

- History of cerebrovascular accident (CVA) within 6 months prior to randomization or that resulted in ongoing neurologic instability

- Active infection or serious underlying medical condition (including any type of active seizure disorder within 12 months prior to randomization) that would impair the ability of the patient to receive study drug

- History of human immunodeficiency virus (HIV) infection or acquired immune deficiency syndrome (AIDS)-related illness or serious acute or chronic illness

- History of any psychiatric or neurologic condition that might impair the patient's ability to understand or to comply with the requirements of the study or to provide informed consent

- Pregnant or breast-feeding females

- Symptomatic brain metastases that are not stable, require steroids, are potentially life threatening, or that have required radiation within 28 days prior to randomization; and/or

- History of allergic reactions attributed to compounds of similar chemical or biologic composition to study drug

Gender: All

Minimum Age: 18 Years

Maximum Age: N/A

Healthy Volunteers: No

Overall Official
Last Name Role Affiliation
Medical Director Study Director Astellas Pharma Global Development
University of California - Los Angeles | Los Angeles, California, 90095, United States
Tulane University Health Services Center | New Orleans, Louisiana, 70112, United States
Oregon Health & Science University | Portland, Oregon, 97239, United States
Virginia Mason Medical Center | Seattle, Washington, 98101, United States
Seattle Cancer Care Alliance University of Washington | Seattle, Washington, 98109, United States
Medical College of Wisconsin | Milwaukee, Wisconsin, 52336, United States
Cliniques Universitaires Saint-Luc | Brussells, 1200, Belgium
Universitair Ziekenhuis Gent | Gent, 9000, Belgium
Hopital Jean Verdier - Dervice d'Hepato-Gastroenterologie | Bondy Cedex, 93143, France
Hôpital Henri Mondor | Creteil cedex, 94010, France
Hopital de la Timone | Marseille Cedex 5, 13385, France
Hopital l'Archet 2 | Nice cedex 03, 6202, France
Hôpital Saint-Antoine | Paris cedex 12, 75012, France
Hôpital de Tenon | Paris cedex 12, 75020, France
Centre Rene Gauducheau | Saint Herblain cedex, 44805, France
Universitatsklinikum Essen | Essen, 45122, Germany
Universitätsklinikum Halle | Halle, 06097, Germany
Universitatsklinikum des Saarlandes | Homburg, 66421, Germany
Universitätsklinikum Magdeburg A.ö.R. | Magdeburg, 39120, Germany
Queen Mary Hospital | Hong Kong, Hong Kong
Fondazione Ca' Granda Ospedale Maggiore Policlinico, Divisione di Gastroenterologia I | Milano, 20122, Italy
Ospedale Fatebenefratelli, Dipartimento Medicina Interna | Napoli, 80123, Italy
IRCCS Istituto Nazionale per lo studio e la cura dei tumori Fondazione G. Pascale-SSD Epatobiliare | Napoli, 80131, Italy
Istituto Mediterraneo per i Trapianti e Terapie ad Alta Specializzazione ISMETT-Dipartimento di Epatologia e Gastroenterologia | Palermo, 90127, Italy
Pusan National University Hospital | Busan, 602-739, Korea, Republic of
Kyungpook National University Hospital | Daegu, 700-721, Korea, Republic of
National Cancer Center | Goyang-si, 410-769, Korea, Republic of
Seoul National University Hospital | Seoul, 110-774, Korea, Republic of
Severance Hospital | Seoul, 120-752, Korea, Republic of
Samsung Medical Center | Seoul, 135-710, Korea, Republic of
Singapore General Hospital | Singapore, 169608, Singapore
Johns Hopkins Singapore International Medical Centre | Singapore, 308433, Singapore
Hospital Clinico Universitario de Santiago de Compostela | Santiago de Compostela, Coruna, 15706, Spain
Hospital Clinic Provincial | Barcelona, 08036, Spain
Hospital Puerta de Hierro Majadahonda | Madrid, 28220, Spain
Clinica Universitaria de Navarra | Pamplona, 31008, Spain
Changhua Christian Hospital | Changhua, 500, Taiwan
Kaohsiung Medical University Chung-Ho Memorial Hospital | Kaohsiung, 807, Taiwan
Taichung Veterans General Hospital | Taichung, 40705, Taiwan
China Medical University Hospital | Taichung, Taiwan
Chang Gung Medical Foundation LinKou Branch | TaoYuan, 333, Taiwan
Location Countries




Hong Kong


Korea, Republic of




United States

Verification Date

August 2018

Responsible Party

Type: Sponsor

Has Expanded Access No
Condition Browse
Number Of Arms 2
Arm Group

Label: Arm A: OSI-906

Type: Experimental

Description: 150 mg BID

Label: Arm B: Placebo

Type: Placebo Comparator

Description: Placebo BID

Patient Data No
Study Design Info

Allocation: Randomized

Intervention Model: Parallel Assignment

Primary Purpose: Treatment

Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

Source: ClinicalTrials.gov